Equibles does not estimate personal net worth.
Get an email with a short summary when Dyadic International Inc publishes a filing, an earnings call transcript or a press release.
Get DYAI alertsDyadic International Inc reported in an 8-K filed June 2, 2025 that Joe Hazelton was appointed President. Dyadic International Inc reported in an 8-K filed June 2, 2025 that Joe Hazelton was appointed President, effective June 2, 2025. Joe Hazelton has spoken on 5 earnings calls across 1 company, most recently for Dyadic International Inc on May 13, 2026. Dyadic International Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyadic International Inc includes Mark Emalfarb (CEO and Board Member), Ping Rawson (CFO), Joseph Hazelton (COO) and 1 other.
“Dyadic's Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately.”
“Dyadic's Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately.”
“As we recently held our full-year 2025 earnings call, Today, we want to build on the updates we provided in March by focusing on the continued operational and commercial progress we're making across the business and why we believe Dyadic is increasingly well-positioned for the future.”
“Since I stepped into the president's role in June of 2025, our focus has been very clear. To accelerate Dyadic's transition from a development stage platform company into a commercial product-driven biotechnology business with multiple paths for revenue.”
“We are increasingly focused on building a strong portfolio of commercial-ready non-pharmaceutical products across the life sciences, bioactives, ingredients, and industrial sectors, areas where our expression platforms offer significant advantages in speed, scalability, and cost efficiency.”
“The primary purpose of the Phase-1 study is to evaluate the safety of the new drug candidate before it proceeds to further clinical studies.”
“I'm pleased with the progress that has been achieved this quarter in the Phase 1 clinical program for our DYAI-100 COVID-19 vaccine candidate. cGMP production and the fill and finish activities of DYAI-100 have been completed.”
Source not stated
Biotechnology · Healthcare
